The role of the epidermal growth factor receptor in breast cancer

被引：58

作者：

Chan, Samuel K.

Hill, Mark E.

Gullick, William J. ^{[1
]}

机构：

[1] Univ Kent, Canc Biol Lab, Res Sch Biosci, Canterbury CT2 7NJ, Kent, England

[2] Kent Oncol Ctr, Maidstone, Kent, England

来源：

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA | 2006年 / 11卷 / 01期

关键词：

breast; ErbB; EGFR; signal transduction; hormone resistance; gefitinib; erlotinib;

D O I：

10.1007/s10911-006-9008-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent trials of drug therapy targeting the erbB receptor HER2 have met with success in breast cancer. The epidermal growth factor receptor or EGFR is a closely related receptor from this same family that is involved in cellular signal transduction and tumor cell growth and survival. Emerging evidence indicates that EGFR is implicated in the development of hormone-resistant breast cancer, and that its activity is intertwined with estrogen receptor. Here, the role of EGFR in breast cancer is reviewed, and data from selected clinical trials of signal transduction inhibition of this cellular target are summarized.

引用

页码：3 / 11

页数：9

共 78 条

[1]

Albain K, 2002, BREAST CANCER RES TR, V76, pS33

[2]

[Anonymous], 2003, Clin Adv Hematol Oncol, V1, P237

[3]

[Anonymous], P AM SOC CLIN ONCOL

[4] Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer [J].

Baselga, J ;

Albanell, J ;

Ruiz, A ;

Lluch, A ;

Gascón, P ;

Guillém, V ;

González, S ;

Sauleda, S ;

Marimón, I ;

Tabernero, JM ;

Koehler, MT ;

Rojo, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5323-5333

[5] The epidermal growth factor receptor family [J].

Bazley, LA ;

Gullick, WJ .

[6]

BEERAM M, 2005, SAN ANT BREAST CANC

[7]

Bianco C, 2002, CLIN CANCER RES, V8, P3250

[8]

BLACKWELL KL, 2004, J CLIN ONCOL, V22, P3006

[9]

BLOOM K, 2005, SAN ANT BREAST CANC

[10]

BRITTON DJ, 2005, BREAST CANC RES TREA, P1

← 1 2 3 4 5 6 7 8 →